{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:17Z","timestamp":1790245637329,"version":"4.1.0"},"reference-count":39,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4435","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T08:59:50Z","timestamp":1528707590000},"source":"Crossref","is-referenced-by-count":15,"title":["HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer"],"prefix":"10.3892","author":[{"given":"Satoshi","family":"Sugita","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Yonemori","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Osako","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"key":"key20200713184944_b1-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20200713184944_b2-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20200713184944_b3-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canep.2013.02.002","article-title":"Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis","volume":"37","author":"Abdollah","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"key20200713184944_b4-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","journal-title":"Lancet"},{"key":"key20200713184944_b5-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: Weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"key20200713184944_b6-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: Split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713184944_b7-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"key20200713184944_b8-ijo-53-02-0725","first-page":"413","article-title":"Mutations of ras genes in human tumors (Review)","volume":"7","author":"Kiaris","year":"1995","journal-title":"Int J Oncol"},{"key":"key20200713184944_b9-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.4155\/fmc.11.121","article-title":"Inhibition of Ras for cancer treatment: The search continues","volume":"3","author":"Baines","year":"2011","journal-title":"Future Med Chem"},{"key":"key20200713184944_b10-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713184944_b11-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans, transfarnesyl thiosalicylic acid","volume":"1452","author":"Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"key20200713184944_b12-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","article-title":"A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice","volume":"18","author":"Weisz","year":"1999","journal-title":"Oncogene"},{"key":"key20200713184944_b13-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/JTO.0b013e318223c099","article-title":"A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations","volume":"6","author":"Riely","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key20200713184944_b14-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","article-title":"Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies","volume":"15","author":"Badar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20200713184944_b15-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/fon.10.71","article-title":"Salirasib in the treatment of pancreatic cancer","volume":"6","author":"Bustinza-Linares","year":"2010","journal-title":"Future Oncol"},{"key":"key20200713184944_b16-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","article-title":"Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer","volume":"30","author":"Laheru","year":"2012","journal-title":"Invest New Drugs"},{"key":"key20200713184944_b17-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/ijc.26139","article-title":"Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: A potential treatment for lymphangioleiomyomatosis","volume":"130","author":"Makovski","year":"2012","journal-title":"Int J Cancer"},{"key":"key20200713184944_b18-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"Zundelevich","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20200713184944_b19-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nmeth.4116","article-title":"A large-scale targeted proteomics assay resource based on an in vitro human proteome","volume":"14","author":"Matsumoto","year":"2017","journal-title":"Nat Methods"},{"key":"key20200713184944_b20-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"key20200713184944_b21-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713184944_b22-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ijc.24390","article-title":"Identification of novel microRNA targets based on microRNA signatures in bladder cancer","volume":"125","author":"Ichimi","year":"2009","journal-title":"Int J Cancer"},{"key":"key20200713184944_b23-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/bjc.2011.23","article-title":"The tumoursuppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer","volume":"104","author":"Yoshino","year":"2011","journal-title":"Br J Cancer"},{"key":"key20200713184944_b24-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"key20200713184944_b25-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"10351","DOI":"10.1158\/0008-5472.CAN-10-0740","article-title":"Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha","volume":"70","author":"Qing","year":"2010","journal-title":"Cancer Res"},{"key":"key20200713184944_b26-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4143\/crt.2004.36.6.343","article-title":"HIF-1alpha: A valid therapeutic target for tumor therapy","volume":"36","author":"Hong","year":"2004","journal-title":"Cancer Res Treat"},{"key":"key20200713184944_b27-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"33834","DOI":"10.18632\/oncotarget.5616","article-title":"The association between let-7, RAS and HIF-1\u03b1 in Ewing Sarcoma tumor growth","volume":"6","author":"Hameiri-Grossman","year":"2015","journal-title":"Oncotarget"},{"key":"key20200713184944_b28-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0092-8674(82)90100-3","article-title":"Isolation of a transforming sequence from a human bladder carcinoma cell line","volume":"29","author":"Shih","year":"1982","journal-title":"Cell"},{"key":"key20200713184944_b29-ijo-53-02-0725","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3892\/ijo.1.7.731","article-title":"H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia","volume":"1","author":"Haliassos","year":"1992","journal-title":"Int J Oncol"},{"key":"key20200713184944_b30-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12013-015-0574-z","article-title":"Bladder cancer and genetic mutations","volume":"73","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"key20200713184944_b31-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"key":"key20200713184944_b32-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ejhg.2013.251","article-title":"HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome","volume":"22","author":"Beukers","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"key20200713184944_b33-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.urolonc.2011.03.004","article-title":"HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population","volume":"31","author":"Pandith","year":"2013","journal-title":"Urol Oncol"},{"key":"key20200713184944_b34-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1038\/cddis.2012.24","article-title":"FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice","volume":"3","author":"Goldberg","year":"2012","journal-title":"Cell Death Dis"},{"key":"key20200713184944_b35-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1158\/1535-7163.MCT-08-0488","article-title":"Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: A convection-enhanced drug delivery study in rats","volume":"7","author":"Goldberg","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20200713184944_b36-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/1476-4598-9-256","article-title":"Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition","volume":"9","author":"Charette","year":"2010","journal-title":"Mol Cancer"},{"key":"key20200713184944_b37-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/1078-0432.CCR-07-1532","article-title":"Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome","volume":"14","author":"Kurzrock","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200713184944_b38-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"key":"key20200713184944_b39-ijo-53-02-0725","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.02.006","article-title":"Multivalent small-molecule Pan-RAS inhibitors","volume":"168","author":"Welsch","year":"2017","journal-title":"Cell"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T11:57:26Z","timestamp":1661428646000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4435","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,11]]}}}